For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230224:nRSX9157Qa&default-theme=true
RNS Number : 9157Q HealthBeacon PLC 24 February 2023
23 February 2023
HealthBeacon plc
Director/PDMR Shareholding
Dublin, Ireland - 23 February 2023: HealthBeacon plc (HBCN.ID) ("HealthBeacon"
or "the Company"), a digital therapeutics company that develops products for
managing injectable medications for patients in the home, today announces that
Jim Joyce, Chief Executive Officer and Co-Founder, has purchased 21,521
ordinary shares at a price of €1.13. Following this purchase Jim Joyce holds
1,833,307 shares representing 10.85% of the Company.
The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of ordinary shares
purchased.
Notification - of Transactions by Persons Discharging Managerial
Responsibilities and Persons Closely Associated with them
This form is required for disclosure of transactions under Article 19 of
Regulation (EU) No 596/2014 of the European Parliament and of the Council of
16 April 2014 on market abuse (Market Abuse Regulation)
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Jim Joyce
2 Reason for the notification
a) Position/status Person discharging managerial responsibility - Chief Executive Officer
b) Initial Notification Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HealthBeacon plc
b) LEI 635400DZJITFJMT8T166
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of €0.0025 each ("HealthBeacon Shares")
Identification code
IE00014QAJZ5
b) Nature of the transaction Purchase of HealthBeacon Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
€1.11 per ordinary share 3,800
€1.10 per ordinary share 5,000
€1.08 per ordinary share 914
€1.15 per ordinary share 11,807
d) Aggregated information
- Aggregated volume
- Price
21,521
€1.13
e) Date of the transaction 23 February 2023
f) Place of the transaction Euronext Growth Market Dublin
g) Additional Information N/A
d)
Aggregated information
- Aggregated volume
- Price
21,521
€1.13
e)
Date of the transaction
23 February 2023
f)
Place of the transaction
Euronext Growth Market Dublin
g)
Additional Information
N/A
Enquiries:
HealthBeacon: Investor.Relations@HealthBeacon.com
Lar Malone
Goodbody (Euronext Listing Sponsor and Broker): +353 (1) 667 0420
David Kearney
Stephen Kane
Drury (Public Relations):
Cathal Barry +353 (0) 87 227 9281
Paul Clifford +353 (0) 87 327 2161
About HealthBeacon plc
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems. The
Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Wave which
integrates with its existing technology. The Company operates across Europe,
North America and the United Kingdom and employs more than 70 people and has
obtained more than 30 design and utility patents. The Company's mission is to
become the world's leading digital therapeutics platform for patients managing
medications in the home.
Ends
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ISENKNBDCBKDBBB